2 weeks Ago By ABMN Staff
XTX Topco Ltd boosted its position in Arvinas, Inc. ( NASDAQ:ARVN – Free Report ) by 44.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 26,599 shares of the company’s stock after buying an additional 8,198 shares during the quarter. XTX Topco Ltd’s holdings in Arvinas were worth $510,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds have also recently made changes to their positions in the company.
JPMorgan Chase & Co. boosted its holdings in Arvinas by 18.7% in the 3rd quarter.
JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after buying an additional 367,343 shares during the period. Edmond DE Rothschild Holding S.
A. bought a new position in shares of Arvinas in the fourth quarter worth $1,534,000. BIT Capital GmbH grew its position in shares of Arvinas by 291.
7% in the fourth quarter. BIT Capital GmbH now owns 263,527 shares of the company’s stock valued at $5,052,000 after purchasing an additional 196,246 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of Arvinas by 42.
0% during the 4th quarter. Kennedy Capital Management LLC now owns 208,992 shares of the company’s stock valued at $4,006,000 after purchasing an additional 61,802 shares during the period. Finally, Norges Bank purchased a new stake in Arvinas during the 4th quarter worth about $23,845,000.
95.19% of the stock is currently owned by institutional investors. Arvinas Stock Up 12.
4 % Shares of NASDAQ:ARVN opened at $8.60 on Monday. The stock has a market cap of $591.
44 million, a PE ratio of -3.10 and a beta of 2.30.
The company’s fifty day moving average is $11.49 and its 200 day moving average is $18.56.
Arvinas, Inc. has a 52 week low of $5.94 and a 52 week high of $37.
38. Wall Street Analyst Weigh In A number of research firms have weighed in on ARVN. The Goldman Sachs Group reduced their target price on Arvinas from $15.
00 to $12.00 and set a “neutral” rating for the company in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $81.
00 target price on shares of Arvinas in a report on Monday, April 7th. Citigroup cut their price target on shares of Arvinas from $28.00 to $19.
00 and set a “neutral” rating for the company in a report on Friday, March 7th. Bank of America decreased their price target on shares of Arvinas from $54.00 to $28.
00 and set a “buy” rating on the stock in a report on Wednesday, March 12th. Finally, Oppenheimer cut Arvinas from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 11th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock.
According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.33. Check Out Our Latest Analysis on Arvinas Insider Buying and Selling In other news, insider Ian Taylor sold 9,020 shares of the firm’s stock in a transaction dated Monday, February 24th.
The shares were sold at an average price of $16.71, for a total value of $150,724.20.
Following the completion of the sale, the insider now directly owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This trade represents a 5.
36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website . Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction dated Tuesday, March 18th.
The shares were sold at an average price of $8.59, for a total transaction of $74,372.22.
Following the transaction, the insider now owns 110,023 shares in the company, valued at $945,097.57. This represents a 7.
30 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold a total of 50,230 shares of company stock valued at $769,402 over the last three months.
5.23% of the stock is owned by company insiders. About Arvinas ( Free Report ) Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Recommended Stories Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter .
.
